<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2024-9.6.4</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-5114</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНФЕКЦИОННЫЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INFECTIOUS DISEASES</subject></subj-group></article-categories><title-group><article-title>Высокая серопревалентность к  SARS-CoV-2 среди медицинских и  немедицинских работников офтальмологического центра</article-title><trans-title-group xml:lang="en"><trans-title>High seroprevalence to  SARS-CoV-2 among healthcare and  non-healthcare workers of  the  ophthalmology center</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1783-5798</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пальянова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Palyanova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пальянова Наталья Валерьевна,</p><p>630060, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Natalia V. Palyanova – Junior Research Officer at the Research Institute of Virology, </p><p>Timakova str. 2, Novosibirsk 630117</p></bio><email xlink:type="simple">natalia.palyanova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чеченин</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Chechenin</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630060, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Mikhail G. Chechenin – Dr. Sc. (Med.), Senior Research Officer, </p><p>Timakova str. 2, Novosibirsk 630117</p></bio><email xlink:type="simple">chechenin1970@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7592-8984</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трунов</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Trunov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630060, г. Новосибирск, ул. Тимакова, 2;</p><p>630096, г. Новосибирск, ул. Колхидская, 10</p></bio><bio xml:lang="en"><p>Alexander N. Trunov – Dr. Sc. (Med.), Professor, Timakova str. 2, Novosibirsk 630117;</p><p>Head of the Scientific Department, Kolkhidskaya str. 10, Novosibirsk 630096</p></bio><email xlink:type="simple">trunov1963@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4561-6517</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соболев</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sobolev</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630060, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Ivan A. Sobolev – Cand. Sc. (Med.), Senior Research Officer, Head of the Laboratory of Genomics and Virus Evolution, </p><p>Timakova str. 2, Novosibirsk 630117</p></bio><email xlink:type="simple">sobolev_i@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9734-0620</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестопалов</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Shestopalov</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630060, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Alexander M. Shestopalov – Dr. Sc. (Med.), Professor, Director of the Research Institute of Virology, </p><p>Timakova str. 2, Novosibirsk 630117</p></bio><email xlink:type="simple">shestopalov2@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной&#13;
медицины»</institution></aff><aff xml:lang="en"><institution>Federal Research Center of Fundamental and Translational Medicine</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины»;&#13;
Новосибирский филиал ФГАУ «НМИЦ «МНТК «Микрохирургия глаза» имени академика С.Н. Фёдорова» Минздрава России</institution></aff><aff xml:lang="en"><institution>Federal Research Center of Fundamental and Translational Medicine;&#13;
Novosibirsk Branch of the S. Fyodorov Eye Microsurgery Federal State Institution</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>28</day><month>12</month><year>2024</year></pub-date><volume>9</volume><issue>6</issue><fpage>34</fpage><lpage>43</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Пальянова Н.В., Чеченин М.Г., Трунов А.Н., Соболев И.А., Шестопалов А.М., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Пальянова Н.В., Чеченин М.Г., Трунов А.Н., Соболев И.А., Шестопалов А.М.</copyright-holder><copyright-holder xml:lang="en">Palyanova N.V., Chechenin M.G., Trunov A.N., Sobolev I.A., Shestopalov A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/5114">https://www.actabiomedica.ru/jour/article/view/5114</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Пандемия COVID-19 вызвала обеспокоенность по поводу безопасности медицинских работников, в то время как немедицинский персонал остался без должного внимания. Сравнение уровней серопревалентности к SARS-CoV-2 и вакцинации в разных группах сотрудников позволяет оценить риск заражения и разработать стратегию по минимизации распространения инфекций в медицинских учреждениях.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Выявить риски заражения SARS-CoV-2 для всех групп работников медицинского центра.</p></sec><sec><title>Методы</title><p>Методы. В середине 2021 г. серопревалентность SARS-CoV-2 проанализировали у 361 сотрудника офтальмологического центра. Уровень специфических антител IgM и IgG сравнивали с данными, указанными в опроснике, включающем информацию о профессии.</p></sec><sec><title>Результаты</title><p>Результаты. В зависимости от рода деятельности рабочие были разделены на 7 групп. Средний показатель серопревалентности среди всех сотрудников составил 82,3 %, а процент вакцинированных сотрудников – 27,42 %. Самый низкий уровень серопревалентности выявлен в группе обслуживающего персонала (55 %), что значительно ниже, чем в группах врачей (84,4 %), медсестёр (85,6 %), административного персонала (82,6 %) и работников столовой (77,7 %). Уровень серопревалентности среди уборщиков составил 84,6 %, а среди работников аптек – 80 %. Самый высокий охват вакцинацией был среди врачей (50 %), самый низкий – среди работников столовой (7,4 %).</p></sec><sec><title>Обсуждение</title><p>Обсуждение. Мы считаем, что высокая заболеваемость связана с бессимптомным распространением SARS-CoV-2.</p></sec><sec><title>Заключение</title><p>Заключение. Высокий риск заражения был у  врачей и  медсестёр, работников аптек, столовых, уборщиц, а также у работников администрации. Противоэпидемические мероприятия для  этих групп позволят снизить распространение инфекционных заболеваний и помогут сохранить здоровье персонала в период сезонного роста заболеваемости.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. The pandemic of COVID-19 raised safety concerns for healthcare workers while non-medical personnel were left unattended. Comparing the levels of seroprevalence to SARS-CoV-2 and vaccination in different employee groups will allows us to assess the risk of infection and develop a strategy to minimize the spread of infections in medical institutions in future.</p></sec><sec><title>The aim</title><p>The aim. To identify the level of seroprevalence to SARS-CoV-2 for seven groups of medical center workers. Methods. The seroprevalence to SARS-CoV-2 was analyzed in 361 employees of the ophthalmology center in mid-2021. Data on the level of specific IgM and IgG antibodies were compared with questionnaire, including occupation data.</p></sec><sec><title>Results</title><p>Results. Depending on occupation, workers were divided into seven groups. The average seroprevalence rate for all employees was 82.3 %, and the percentage of vaccinated employees was 27.4 %. The lowest level of seroprevalence was found in the group of maintenance staff (55.0 %) which is significantly lower (p ˂ 0.05) than in the groups of doctors (84.4 %), nurses (85.6 %), administrative stuff (82.6 %) and cafeteria stuff (77.7 %). The seroprevalence rate for cleaning staff was 84.6 % and for pharmacy workers it was 80 %. The highest vaccination coverage was among doctors – 50.0 %, the lowest was among cafeteria and kitchen staff – 7.4 %.</p></sec><sec><title>Discussion</title><p>Discussion. We believe the high seroprevalence is associated with asymptomatic spread of SARS-CoV-2.</p></sec><sec><title>Conclusions</title><p>Conclusions. High seroprevalence was among doctors and nurses, pharmacy workers, canteen workers, cleaners, as well as administration workers. Anti-epidemic measures for these groups will reduce the spread of  infectious diseases and help retain staff during the seasonal increase in incidence.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>SARS-Sov-2</kwd><kwd>серопревалентность</kwd><kwd>вакцинация</kwd><kwd>работники здравоохранения</kwd><kwd>сотрудники</kwd><kwd>не являющиеся работниками здравоохранения</kwd><kwd>IgM</kwd><kwd>IgG</kwd></kwd-group><kwd-group xml:lang="en"><kwd>SARS-CoV-2</kwd><kwd>seroprevalence</kwd><kwd>vaccination</kwd><kwd>healthcare workers</kwd><kwd>non-healthcare workers</kwd><kwd>IgM</kwd><kwd>IgG</kwd></kwd-group><funding-group><funding-statement xml:lang="en">In this research collecting of the biological material was funded by state assignment from the Ministry of Science and Higher Education of Russian Federation 122120600015-2, and analyzing of the data and laboratory diagnostics were funded by  the  Russian Science Foundation grant project No. 23-64-00005.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Liviero F, Volpin A, Furlan P, Battistella M, Broggio A, Fabris L, et al. The impact of SARS-CoV-2 on healthcare workers of a large University Hospital in the Veneto Region: Risk of infection and clinical presentation in relation to different pandemic phases and some relevant determinants. Front Public Health. 2023; 11: 1250911. doi: 10.3389/fpubh.2023.1250911</mixed-citation><mixed-citation xml:lang="en">Liviero F, Volpin A, Furlan P, Battistella M, Broggio A, Fabris L, et al. The impact of SARS-CoV-2 on healthcare workers of a large University Hospital in  the Veneto Region: Risk of  infection and clinical presentation in relation to different pandemic phases and some relevant determinants. Front Public Health. 2023; 11: 1250911. doi: 10.3389/fpubh.2023.1250911</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Palyanova N, Sobolev I, Alekseev A, Glushenko A, Kazachkova E, Markhaev A, et al. Genomic and epidemiological features of COVID-19 in the Novosibirsk Region during the beginning of the pandemic. Viruses. 2022; 14(9): 2036. doi: 10.3390/v14092036</mixed-citation><mixed-citation xml:lang="en">Palyanova N, Sobolev I, Alekseev A, Glushenko A, Kazachkova E, Markhaev A, et al. Genomic and epidemiological features of  COVID-19 in  the  Novosibirsk Region during the  beginning of the pandemic. Viruses. 2022; 14(9): 2036. doi: 10.3390/v14092036</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Metzger C, Leroy T, Bochnakian A, Jeulin H, GegoutPetit A, Legrand K, et al. Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic. PLoS One. 2023; 18(4): e0269104. doi: 10.1371/journal.pone.0269104</mixed-citation><mixed-citation xml:lang="en">Metzger  C, Leroy T, Bochnakian  A, Jeulin  H, GegoutPetit  A, Legrand  K, et  al. Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic. PLoS One. 2023; 18(4): e0269104. doi: 10.1371/journal.pone.0269104</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Moreno-Medina K, Sáenz Pérez LD, Villar JC, Váquiro Herrera E, Pérez Franco JE, Varón-Vega FA, et al. SARS-CoV-2 seroprevalence in workers from a Colombian University Hospital. Occup Med (Lond). 2023; 73(3): 128-132. doi: 10.1093/occmed/kqad003</mixed-citation><mixed-citation xml:lang="en">Moreno-Medina K, Sáenz Pérez LD, Villar JC, Váquiro Herrera E, Pérez Franco JE, Varón-Vega FA, et al. SARS-CoV-2 seroprevalence in workers from a Colombian University Hospital. Occup Med (Lond). 2023; 73(3): 128-132. doi: 10.1093/occmed/kqad003</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tariverdi M, Mohammadi H, Hassanzadeh F, Tamaddondar M. Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children’s Hospital. BMC Infect Dis. 2024; 24(1): 253. doi: 10.1186/s12879-023-08863-z</mixed-citation><mixed-citation xml:lang="en">Tariverdi  M, Mohammadi  H, Hassanzadeh  F, Tamaddondar M. Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in  staff members of  Bandar Abbas Children’s Hospital. BMC Infect Dis. 2024; 24(1): 253. doi: 10.1186/s12879-023-08863-z</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Williamson JC, Wierzba TF, Santacatterina M, Munawar I, Seals AL, Pittman Ballard CA, et al.; North Carolina sites of the COVID-19 Community Research Partnership. Analysis of accumulated SARS-CoV-2 seroconversion in North Carolina: The COVID-19 Community Research Partnership. PLoS One. 2022; 17(3): e0260574. doi: 10.1371/journal.pone.0260574</mixed-citation><mixed-citation xml:lang="en">Williamson  JC, Wierzba TF, Santacatterina  M, Munawar  I, Seals  AL, Pittman Ballard  CA, et  al.; North Carolina sites of  the  COVID-19 Community Research Partnership. Analysis of  accumulated SARS-CoV-2 seroconversion in  North Carolina: The COVID-19 Community Research Partnership. PLoS One. 2022; 17(3): e0260574. doi: 10.1371/journal.pone.0260574</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Krieger EA, Samodova OV, Schepina IV, Shagrov LL, Zvezdina YuM. Humoral immunity to new coronavirus infection and vitamin D level in healthcare workers. Journal Infectology. 2023; 15(2): 93-104. (In Russ.) doi: 10.22625/2072-6732-2023-15-2-93-104</mixed-citation><mixed-citation xml:lang="en">Krieger  EA, Samodova  OV, Schepina  IV, Shagrov  LL, Zvezdina YuM. Humoral immunity to new coronavirus infection and  vitamin  D level in  healthcare workers. Journal Infectology. 2023; 15(2): 93-104. (In Russ.) doi: 10.22625/2072-6732-2023-15-2-93-104</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Blokh AI, Panyushkina II, Pakhtusova PO, Sergeeva IV, Levahina LI, Burashnikova IP, et al. Assessment of seroconversion to SARS-CoV-2 in health care unit personnel. Epidemiology and Vaccinal Prevention. 2021; 20(5): 32-38. (In Russ.) doi: 10.31631/2073-3046-2021-20-5-32-38</mixed-citation><mixed-citation xml:lang="en">Blokh  AI, Panyushkina  II, Pakhtusova  PO, Sergeeva  IV, Levahina LI, Burashnikova IP, et al. Assessment of seroconversion to SARS-CoV-2 in health care unit personnel. Epidemiology and Vaccinal Prevention. 2021; 20(5): 32-38. (In Russ.) doi: 10.31631/2073-3046-2021-20-5-32-38</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARSCoV-2 infection. J Med Virol. 2020; 92(6): 589-594. doi: 10.1002/jmv.25725</mixed-citation><mixed-citation xml:lang="en">Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARSCoV-2 infection. J Med Virol. 2020; 92(6): 589-594. doi: 10.1002/jmv.25725</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lacorzana J, Ortiz-Perez S, Rubio Prats M. Incidence of COVID-19 among ophthalmology professionals. Med Clin (Barc). 2020; 155(5): 225. doi: 10.1016/j.medcli.2020.05.018</mixed-citation><mixed-citation xml:lang="en">Lacorzana  J, Ortiz-Perez  S, Rubio Prats  M. Incidence of COVID-19 among ophthalmology professionals. Med Clin (Barc). 2020; 155(5): 225. doi: 10.1016/j.medcli.2020.05.018</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sacchi M, Lizzio RAU, Villani E, Tagliabue E, Monsellato G, Pajardi G, et al. Prevalence of SARS-CoV-2 amongst ophthalmologists throughout the first and second waves of the pandemic. Medicine (Baltimore). 2021; 100(50): e28192. doi: 10.1097/MD.0000000000028192</mixed-citation><mixed-citation xml:lang="en">Sacchi M, Lizzio RAU, Villani E, Tagliabue E, Monsellato G, Pajardi  G, et  al. Prevalence of  SARS-CoV-2 amongst ophthalmologists throughout the  first and second waves of  the  pandemic. Medicine (Baltimore). 2021; 100(50): e28192. doi: 10.1097/MD.0000000000028192</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Palyanova NV, Sobolev IA, Palyanov AY, Kurskaya OG, Komissarov AB, Danilenko DM, et al. The development of the SARSCoV-2 epidemic in different regions of Siberia in the 2020–2022 period. Viruses. 2023; 15(10): 2014. doi: 10.3390/v15102014</mixed-citation><mixed-citation xml:lang="en">Palyanova  NV, Sobolev  IA, Palyanov  AY, Kurskaya  OG, Komissarov AB, Danilenko DM, et al. The development of the SARSCoV-2 epidemic in different regions of Siberia in the 2020–2022 period. Viruses. 2023; 15(10): 2014. doi: 10.3390/v15102014</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yandex DataLens. URL: https://datalens.yandex/7o7is1q6ikh23?tab=X1&amp;state=42db05f5180 [date of access: 7.05.2024].</mixed-citation><mixed-citation xml:lang="en">Yandex DataLens. URL:  https://datalens.yandex/7o7is1q6ikh23?tab=X1&amp;state=42db05f5180 [date of  access: 7.05.2024].</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Analysis of four-field contingency tables (comparison of percentages in two groups) (online calculator). Medstatistic. (In Russ.). URL: https://medstatistic.ru/calculators/calchi.html [date of access: 7.05.2024].</mixed-citation><mixed-citation xml:lang="en">Analysis of  four-field contingency tables (comparison of  percentages in  two groups) (online calculator). Medstatistic. (In Russ.). URL: https://medstatistic.ru/calculators/calchi.html [date of access: 7.05.2024].</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Calculate confidence limits for a sample proportion. URL: https://epitools.ausvet.com.au/ciproportion [date of access: 1.12.2024].</mixed-citation><mixed-citation xml:lang="en">Calculate confidence limits for  a  sample proportion. URL: https://epitools.ausvet.com.au/ciproportion [date of access: 1.12.2024].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2020; 15(12): e0244126. doi: 10.1371/journal.pone.0244126</mixed-citation><mixed-citation xml:lang="en">Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman  D, et  al. Antibody response to  SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2020; 15(12): e0244126. doi: 10.1371/journal.pone.0244126</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wang K, Long QX, Deng HJ, Hu J, Gao QZ, Zhang GJ, et al. Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Clin Infect Dis. 2021; 73(3): e531-e539. doi: 10.1093/cid/ciaa1143</mixed-citation><mixed-citation xml:lang="en">Wang K, Long QX, Deng HJ, Hu J, Gao QZ, Zhang GJ, et al. Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Clin Infect Dis. 2021; 73(3): e531-e539. doi: 10.1093/cid/ciaa1143</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fatkhutdinova LM, Badamshina GG, Sizova EP, Patyashina MA, Stavropolskaya LV, Gabidinova GF, et al. Immune response to SARS-CoV-2 and the risk of COVID-19 among different groups of healthcare workers. Russian Journal of Occupational Health and Industrial Ecology. 2021; 61(5): 286-304. (In Russ.). doi: 10.31089/1026-9428-2021-61-5-286-304</mixed-citation><mixed-citation xml:lang="en">Fatkhutdinova LM, Badamshina GG, Sizova EP, Patyashina  MA, Stavropolskaya  LV, Gabidinova  GF, et  al. Immune response to SARS-CoV-2 and the risk of COVID-19 among different groups of  healthcare workers. Russian Journal of Occupational Health and Industrial Ecology. 2021; 61(5): 286-304. (In  Russ.). doi: 10.31089/1026-9428-2021-61-5-286-304</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wiggen TD, Bohn B, Ulrich AK, Stovitz SD, Strickland AJ, Naumchik BM, et al. SARS-CoV-2 seroprevalence among healthcare workers. PLoS One. 2022; 17(4): e0266410. doi: 10.1371/journal.pone.0266410</mixed-citation><mixed-citation xml:lang="en">Wiggen TD, Bohn B, Ulrich AK, Stovitz SD, Strickland AJ, Naumchik BM, et al. SARS-CoV-2 seroprevalence among healthcare workers. PLoS One. 2022; 17(4): e0266410. doi:  10.1371/journal.pone.0266410</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Agafonova EV, Kulikov SN, Reshetnikova ID, Tyurin YuA, Gilyazutdinova GF, Lopushov DV, et al. Seroprevalence study results to SARS-CoV-2 in healthcare workers: age and professional aspects. Epidemiology and Vaccinal Prevention. 2021; 20(2): 49-57. (In Russ.). doi: 10.31631/2073-3046-2021-20-2-49-57</mixed-citation><mixed-citation xml:lang="en">Agafonova EV, Kulikov SN, Reshetnikova ID, Tyurin YuA, Gilyazutdinova GF, Lopushov DV, et al. Seroprevalence study results to SARS-CoV-2 in healthcare workers: age and professional aspects. Epidemiology and Vaccinal Prevention. 2021; 20(2): 49-57. (In Russ.). doi: 10.31631/2073-3046-2021-20-2-49-57</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">de Visscher N, Holemans X, Gillain A, Kornreich A, Lagasse R, Piette P, et al. SARS-CoV-2 seroprevalence among healthcare workers after the first and second pandemic waves. Viruses. 2022; 14(7): 1535. doi: 10.3390/v14071535</mixed-citation><mixed-citation xml:lang="en">de Visscher  N, Holemans  X, Gillain  A, Kornreich  A, Lagasse R, Piette P, et al. SARS-CoV-2 seroprevalence among healthcare workers after the first and second pandemic waves. Viruses. 2022; 14(7): 1535. doi: 10.3390/v14071535</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ige FA, Ohihoin GA, Osuolale K, Dada A, Onyia N, Johnson A, et al. Seroprevalence of SARS-CoV-2 IgG among healthcare workers in Lagos, Nigeria. PLoS One. 2023; 18(10): e0292440. doi: 10.1371/journal.pone.0292440</mixed-citation><mixed-citation xml:lang="en">Ige FA, Ohihoin GA, Osuolale K, Dada A, Onyia N, Johnson A, et al. Seroprevalence of SARS-CoV-2 IgG among healthcare workers in  Lagos, Nigeria. PLoS One. 2023; 18(10): e0292440. doi: 10.1371/journal.pone.0292440</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. Protocol for assessment of potential risk factors for coronavirus disease 2019 (COVID‐19) among health workers in a health care setting. Version: 2.2. 2020. WHO/2019-nCoV/HCW_risk_factors_protocol/2020.3</mixed-citation><mixed-citation xml:lang="en">WHO. Protocol for assessment of potential risk factors for coronavirus disease 2019 (COVID‐19) among health workers in a health care setting. Version: 2.2. 2020. WHO/2019-nCoV/HCW_risk_factors_protocol/2020.3</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
